The Refinement of Uncertainty/Safety Factors in Risk Assessment by the Incorporation of Data on Toxicokinetic Variability in Humans
Open Access
- 30 March 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 86 (1) , 20-26
- https://doi.org/10.1093/toxsci/kfi160
Abstract
The derivation of safe levels of exposure in humans for compounds that are assumed to cause threshold toxicity has relied on the application of a 100-fold uncertainty factor to a measure for the threshold, such as the no observed adverse effect level (NOAEL) or the benchmark dose (BMD). This 100-fold safety factor consists of the product of two 10-fold factors allowing for human variability and interspecies differences. The International Programme on Chemical Safety has suggested the subdivision of these 10-fold factors to allow for variability in toxicokinetics and toxicodynamics. This subdivision allows the replacement of the default uncertainty factors with a chemical-specific adjustment factor (CSAF) when suitable data are available. This short review describes potential options to refine safety factors used in risk assessment, with particular emphasis on pathway-related uncertainty factors associated with variability in kinetics. These pathway-related factors were derived from a database that quantified interspecies differences and human variability in phase I metabolism, phase II metabolism, and renal excretion. This approach allows metabolism and pharmacokinetic data in healthy adults and subgroups of the population to be incorporated in the risk-assessment process and constitutes an intermediate approach between simple default factors and chemical-specific adjustment factors.Keywords
This publication has 47 references indexed in Scilit:
- Impact of inter‐individual differences in drug metabolism and pharmacokinetics on safety evaluationFundamental & Clinical Pharmacology, 2004
- Hazard identification by methods of animal-based toxicologyFood and Chemical Toxicology, 2001
- Human variability in glucuronidation in relation to uncertainty factors for risk assessmentFood and Chemical Toxicology, 2001
- Uncertainty factors for chemical risk assessmentFood and Chemical Toxicology, 2001
- Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genesPharmacogenetics and Genomics, 1999
- Carcinogen risk assessment. Can we harmonise?Toxicology Letters, 1998
- 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*Clinical Pharmacology & Therapeutics, 1998
- Onset of xenobiotic metabolism in children: Toxicological implicationsFood Additives & Contaminants, 1998
- Principles of Drug Biodisposition in the NeonateClinical Pharmacokinetics, 1988
- A new method for determining allowable daily intakes*1Fundamental and Applied Toxicology, 1984